FMR1 and fragile X syndrome: Although an invaluable resource for drug screening and evaluating phenotype development within the in vivo niche, mouse models of FXS do not recapitulate the molecular hallmarks of the FXS mutation as they occur in humans, in particular hyper-methylation of the FMR1 promoter (Brouwer et al., 2007).